Conference abstract · 16 Oct 2017
Conference abstractPublished 2018
Interchangeability: Can this be established without switching clinical trial?
Celerion Inc., U
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The Biologics Price competition and Innovation Act of 2009 (BPCIA) created an abbreviated pathway for the FDA licensure of biologics that are “biosimilar” or “interchangeable” to a USA-approved reference product. . Under the act, and based on subsequent FDA guidances, a biosimilar is defined as a biologic that is highly similar to the reference product, and there are no clinically meaningful differences between the two products in terms of safety, purity and potency. A biosimilar is considered interchangeable if it can be expected to produce the same clinical result as the reference product. It is also expected that the risk, in terms of safety or diminished efficacy, of switching the two products in the same patient is no greater than when administering the reference product without switching. It should be noted that only an interchangeable product may be substituted for the reference product without the intervention of the prescribing health care provider. As the name of BPCIA suggests, the original intent of this regulation was to spur innovation which in turn will and help bring these life-saving biologics to market quickly and in a cost-effective manner. Reviews of the approaches used for currently approved biosimilars suggest that most manufacturers utilize traditional technologies and processes to bring these drugs to market. The result is a long approval time and modest savings. In order to realize the true benefit from biosimilar or interchangeable products, we need innovation. We also need, as stated by Dr. Steven Kozlowski, M.D. Director, Office of Biotechnology Products, FDA, “cultural and cognitive transformation.” This presentation will make a case for using fingerprinting-like biosimilarity tool combined with a predictive immunogenicity solution using state of the art data modeling to demonstrate the interchangeability of an approved biosimilars product without any additional clinical trial. A case study using bevacizumab will be utilized to demonstrate biosimilarity and interchangeability.
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 16 Oct 2017
Interchangeability, switch ability and substitution of biosimilars drug products
Conference abstract · 20 Feb 2012
Using time-course metabolomics to characterize the early interchange of substrates and putative signals during the establishment of the Populus-Laccaria symbiosis
Conference abstract
Using time-course metabolomics to characterize the early interchange of substrates and putative signals during the establishment of the Populus-Laccaria symbiosis
Research article · 25 Aug 2014
Switching to Iloperidone: An Omnibus of Clinically Relevant Observations from a 12-Week, Open-Label, Randomized Clinical Trial in 500 Persons with Schizophrenia
More from this journal
The newest in Journal of Nephrology & Renal Diseases.
Opinion · 4 Dec 2023
Navigating the Path to Diagnosis: Understanding Kidney Diseases
Opinion · 4 Dec 2023
Unveiling Diuretics: A Comprehensive Exploration of a Vital Drug Class
Perspective · 4 Dec 2023
The Silent and Progressive Threat of Hypertensive Nephropathy: Risk Factors and Treatment Options
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Renal Diseases
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Rafiq Islam”

